Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Enanta Pharmaceuticals Inc ENTA

Healthcare Biotechnology
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ENTA)

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Business Wire 10 hours ago

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

Business Wire 5 days ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

Business Wire February 10, 2025

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire January 8, 2025

Enanta Pharmaceuticals to Appeal Ruling Related to '953 Patent Infringement Lawsuit

Business Wire December 24, 2024

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Business Wire December 9, 2024

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

Business Wire December 6, 2024

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024

Business Wire November 25, 2024

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

Business Wire September 26, 2024
View More News ››

Opinion & Analysis (NDAQ:ENTA)

Biopharma Starts 'Key Catalyst Period,' H2/19, with Clinical Trial in New Indication

Streetwise Reports July 11, 2019

Biotech Reports 'Eye-Catching, Topline Results' from RSV Vaccine Study

Streetwise Reports June 21, 2019

U.S. Biopharma's 'Biggest Stock Moving Event' Imminent

Streetwise Reports May 27, 2019
View More Opinion ››

Bullboard Posts (NDAQ:ENTA)

Using technical analysis for this stock.

This is a good companyand it is time to get on board with it.
coolfooldumbguy - February 13, 2025
View more Bullboard ››

dynaCERT Inc.

dynaCERT Inc.

dynaCERT Inc. is a Canada-based company, which manufactures and distributes carbon emission reduction technology along with ...
View More »